Pharmaceuticals
Dermatophytic Onychomycosis Therapeutics Market

Dermatophytic Onychomycosis Therapeutics Market Size, Share, Trends, Growth, and Regional Forecasts 2025 - 2032

Dermatophytic Onychomycosis Therapeutics Market by Treatment Type (Drug-Based Treatment, Laser Therapy, Photodynamic Therapy, Combination Therapy), by Indication, by End-user, and Regional Analysis for 2025 - 2032

ID: PMRREP5840

April 2025

336 Pages

Author : Abhijeet Surwase

Healthcare

Preview Segmentation

Market Dynamics

Driver - Rise in Diabetic Population

The global increase in the diabetic population is a major factor driving the growth of the antifungal treatment market. Diabetes weakens the immune system and impairs peripheral circulation, creating an ideal environment for fungal infections particularly toenail infections such as onychomycosis. According to the American Diabetes Association (ADA), fungal nail infections are often underdiagnosed in individuals with diabetes. However, if left untreated, they can lead to serious foot complications such as ulcers and even amputations. Research indicates that onychomycosis affects 22–35% of people with diabetes making them two to three times more likely to develop the condition compared to non-diabetics.

With a growing emphasis on preventing complications in diabetic patients, there has been increased innovation in antifungal treatments. Pharmaceutical companies are developing more effective and safer antifungal medications, both topical creams and oral pills, specifically designed to meet the needs of diabetic individuals. These treatments are easy to use, widely accessible, and tailored to address the unique challenges faced by the user. The rise in diabetes rates and the increased risk of fungal nail infections prompts healthcare systems to enhance their strategies for managing onychomycosis thereby driving demand for improved treatment solutions.

Restraint - Prolonged Treatment and High Relapse Rate

Dermatophytic onychomycosis, being a slow-progressing and deeply embedded nail infection, is difficult to completely cure. Even with prolonged antifungal therapy spanning several months, many patients experience only partial clearance of the infection. This is primarily due to poor drug penetration through the nail plate, suboptimal patient adherence, and the ability of dermatophytes to persist in the nail bed or surrounding skin unnoticed.

Relapses are common with recurrence rates ranging between 10% and 53% within a year post-treatment, depending on the drug used and the patient’s overall health. The high relapse rate not only frustrates patients but also diminishes trust in available therapeutics, leading to lower re-treatment rates and poor compliance with follow-up regimens. Additionally, repeated cycles of infection can result in more resistant fungal strains, further complicating treatment efforts.

Opportunity - Diabetic-Specific Antifungal Treatments

The demand for antifungal treatments tailored to the unique needs of diabetic patients presents a high-potential market opportunity. Individuals with diabetes often experience impaired blood circulation, weakened immune responses, and delayed wound healing, making them significantly more vulnerable to chronic and recurring fungal infections such as dermatophytic onychomycosis. Traditional antifungal medications may not be optimal for this group, as they can carry systemic toxicity risks or lack the efficacy due to reduced absorption in compromised tissues.

Get Your CustomizationGet Your Customization

Category Wise Insights

Treatment Type Insights

The drug-based treatment segment dominates due to its proven efficacy, broad clinical acceptance, and accessibility. Oral and topical antifungal medications, such as terbinafine and efinaconazole, remain the first-line choice for most healthcare providers, owing to decades of research, regulatory approvals, and real-world effectiveness. Laser therapy ranks next as an emerging, non-invasive alternative that appeals to patients seeking quicker, localized results without systemic side effects. While Photodynamic therapy (PDT) is a promising innovation, its adoption is constrained by complex treatment protocols and limited practitioner expertise. Combination therapy, which merges pharmacological and device-based approaches, is gaining traction, especially for recurrent or resistant infections.

Indication Type Insights

Distal subungual onychomycosis (DSO) stands as the leading indication segment in the market owing to its overwhelming prevalence and clinical complexity. Representing approximately 85–90% of all dermatophyte-related nail infections, DSO primarily affects the toenails and originates at the nail bed near the tip of the nail. White superficial onychomycosis (WSO) and proximal subungual onychomycosis (PSO) are emerging segments, though less prevalent. WSO is more superficial and easier to treat but accounts for a smaller patient population. PSO, while rare, is clinically significant as it may signal underlying immune suppression, such as in HIV-positive patients. Candidal onychomycosis is more common in fingernails and is associated with chronic exposure to moisture, particularly in individuals with frequent handwashing or certain occupations. Total dystrophic onychomycosis is often the final stage of untreated cases and represents a niche but complex segment requires advanced therapy.

End-user Insights

Retail sales dominate the market due to the high prevalence of self-treatment and easy accessibility of over-the-counter (OTC) antifungal products. Many individuals suffering from nail fungal infections tend to underestimate the condition’s severity, opting for convenient, non-prescription remedies available at pharmacies, supermarkets, and online platforms. This behavior is further supported by the social stigma associated with fungal infections, prompting patients to seek discreet, at-home solutions rather than visiting clinics.

dermatophytic onychomycosis therapeutics market insights and key trends

Regional Insights and Trends

North America Dermatophytic Onychomycosis Therapeutics Market Trends

The demand for advanced, fast-acting and minimally invasive treatment options such as topical agents, oral antifungals, and laser therapies, continues to drive innovation and growth. Moreover, strong pharmaceutical R&D, regulatory support for new drug approvals, and the presence of major market players contribute to the region’s dominance. Also, in the U.S., the dermatophytic onychomycosis therapeutics market is fueled by the rising cases of fungal nail infections, consumer preference for aesthetic nail health, and growing awareness around early diagnosis. The country also benefits from a highly commercialized healthcare system and the rapid adoption of new therapeutic technologies making it the primary revenue contributor in the region.

Europe Dermatophytic Onychomycosis Therapeutics Market Trends

European consumers often prefer natural or non-invasive treatments, contributing to the popularity of herbal and alternative antifungal options. Additionally, public healthcare systems across Europe tend to emphasize cost-effective therapies, influencing prescription patterns toward generics and long-established medications. There is also a growing interest in pediatric care and preventive strategies across countries such as Germany and the U.K., reflecting a proactive stance on foot health.

Asia Pacific Dermatophytic Onychomycosis Therapeutics Market Trends

The increasing use of traditional medicine systems such as Ayurveda and Traditional Chinese Medicine are integrated with modern therapeutics. The rapid digitalization in healthcare enables tele-dermatology services, improving diagnosis rates in remote areas. The youthful population is becoming more image-conscious, boosting demand for aesthetic nail treatments and external appearance.

Request Free sampleRequest Free sample

Competitive Landscape

The global dermatophytic onychomycosis therapeutics market is fragmented, marked by a mix of global pharmaceutical giants and emerging biotech firms. Competition is fueled by the demand for faster, more effective, and side-effect-free treatments. Strategic collaborations, product launches, and patent developments are common, while increasing interest in combination therapies and non-invasive treatments is shaping future competitive strategies.

Key Industry Developments

In January 2024, Vanda Pharmaceuticals Inc. (Vanda) announced that the U.S. Food and Drug Administration (FDA) had approved its Investigational New Drug (IND) application to evaluate VTR-297 for the treatment of onychomycosis.
In December 2022, Bausch Health Companies Inc. announced that it had filed a patent for a method aimed at treating onychomycosis. This patent filing strengthened the company's position in the global market.

Companies Covered in Dermatophytic Onychomycosis Therapeutics Market

Bausch Health
Galderma S.A.
Novartis AG
Pfizer, Inc.
Moberg Pharma AB
Bayer AG
Dr. Reddy’s Laboratories Ltd.
Cipla Ltd.
Medimetriks Pharmaceuticals, Inc.
Sanofi S.A.
GlaxoSmithKline Plc.
Teva Pharmaceutical Industries Ltd.
Cardinal Health Inc.
Viatris Inc.
Almirall, S.A
Vanda Pharmaceuticals Inc.
Others

Frequently Asked Questions

The global dermatophytic onychomycosis therapeutics market is estimated to increase from US$ 7,074.7 Mn in 2025 to US$ 10,602.8 Mn in 2032.

Increasing cases of onychomycosis, especially among the elderly and diabetic populations, are driving demand for effective treatments.

The market is projected to record a CAGR of 6.0% during the forecast period from 2025 to 2032.

Tele-dermatology and mobile health platforms present new avenues for diagnosis, prescription, and patient monitoring.

Some leading players in the dermatophytic onychomycosis therapeutics market include Bausch Health, Galderma S.A., Novartis AG, Pfizer, Inc., Moberg Pharma AB, and others.

Top-Down Market Sizing	Bottom-Up Market Sizing
Universe Definition: Total global/regional market identification	Unit Economics: Average transaction values, purchase frequencies, customer lifecycle
Segmentation Filters: Geographic, demographic, and behavioral constraints	Customer Segmentation: Detailed buyer persona development and sizing
Market Share Analysis: Competitive landscape assessment and share allocation	Penetration Analysis: Market penetration rates by segment and geography
Growth Rate Application: Historical trends and forward-looking growth assumptions	Scaling Methodology: Extrapolation techniques with confidence intervals

Interested in this report?

Request customization, ask for expert consulting, access a sample report, or simply express your interest—our team will assist you with the right insights and solutions.

Request Custom VersionRequest Custom Version

Clients

Media Citation

Get In Touch

Loading page data

Please wait a moment

Executive Summary
1. Global Dermatophytic Onychomycosis Therapeutics Market Snapshot, 2025 and 2032
2. Market Opportunity Assessment, 2025 - 2032, US$ Mn
3. Key Market Trends
4. Future Market Projections
5. Premium Market Insights
6. Industry Developments and Key Market Events
7. PMR Analysis and Recommendations
Market Overview
1. Market Scope and Definition
2. Market Dynamics
  1. Drivers
  2. Restraints
  3. Opportunity
  4. Challenges
  5. Key Trends
3. Macro-Economic Factors
  1. Global Sectorial Outlook
  2. Global GDP Growth Outlook
4. COVID-19 Impact Analysis
5. Forecast Factors - Relevance and Impact
Value Added Insights
1. Regulatory Landscape
2. Treatment Adoption Analysis
3. Disease Epidemiology
4. Pipeline Analysis
5. Reimbursement Scenario
6. Value Chain Analysis
7. Key Deals and Mergers
8. PESTLE Analysis
9. Porter’s Five Force Analysis
Global Dermatophytic Onychomycosis Therapeutics Market Outlook:
1. Key Highlights
  1. Market Size (US$ Mn) and Y-o-Y Growth
  2. Absolute $ Opportunity
2. Market Size (US$ Mn) Analysis and Forecast
  1. Historical Market Size (US$ Mn) Analysis, 2019-2024
  2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
3. Global Dermatophytic Onychomycosis Therapeutics Market Outlook: Treatment Type
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Mn) Analysis, By Treatment Type, 2019 - 2024
  3. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2025 - 2032
    1. Drug-Based Treatment
      1. Topical Antifungals
      2. Oral Antifungals
    2. Laser Therapy
    3. Photodynamic Therapy
    4. Combination Therapy
  4. Market Attractiveness Analysis: Treatment Type
4. Global Dermatophytic Onychomycosis Therapeutics Market Outlook: Indication
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Mn) Analysis, By Indication, 2019 - 2024
  3. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025 - 2032
    1. Distal Subungual Onychomycosis
    2. White Superficial Onychomycosis
    3. Proximal Subungual Onychomycosis
    4. Candidal Onychomycosis
    5. Total Dystrophic Onychomycosis
  4. Market Attractiveness Analysis: Indication
5. Global Dermatophytic Onychomycosis Therapeutics Market Outlook: End User
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Mn) Analysis, By End User, 2019 - 2024
  3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025 - 2032
    1. Institutional Sales
      1. Hospitals
      2. Dermatology Clinics
    2. Retail Sales
      1. Retail Pharmacies
      2. Drug Stores
      3. Mail Order Pharmacies & Online Sales
  4. Market Attractiveness Analysis: End User
Global Dermatophytic Onychomycosis Therapeutics Market Outlook: Region
1. Key Highlights
2. Historical Market Size (US$ Mn) Analysis, By Region, 2019 - 2024
3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025 - 2032
  1. North America
  2. Europe
  3. East Asia
  4. South Asia and Oceania
  5. Latin America
  6. Middle East & Africa
4. Market Attractiveness Analysis: Region
North America Dermatophytic Onychomycosis Therapeutics Market Outlook:
1. Key Highlights
2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2024
  1. By Country
  2. By Treatment Type
  3. By Indication
  4. By End User
3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025 - 2032
  1. U.S.
  2. Canada
4. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2025 - 2032
  1. Drug-Based Treatment
    1. Topical Antifungals
    2. Oral Antifungals
  2. Laser Therapy
  3. Photodynamic Therapy
  4. Combination Therapy
5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025 - 2032
  1. Distal Subungual Onychomycosis
  2. White Superficial Onychomycosis
  3. Proximal Subungual Onychomycosis
  4. Candidal Onychomycosis
  5. Total Dystrophic Onychomycosis
6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025 - 2032
  1. Institutional Sales
    1. Hospitals
    2. Dermatology Clinics
  2. Retail Sales
    1. Retail Pharmacies
    2. Drug Stores
    3. Mail Order Pharmacies & Online Sales
7. Market Attractiveness Analysis
Europe Dermatophytic Onychomycosis Therapeutics Market Outlook:
1. Key Highlights
2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2024
  1. By Country
  2. By Treatment Type
  3. By Indication
  4. By End User
3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025 - 2032
  1. Germany
  2. France
  3. U.K.
  4. Italy
  5. Spain
  6. Russia
  7. Türkiye
  8. Rest of Europe
4. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2025 - 2032
  1. Drug-Based Treatment
    1. Topical Antifungals
    2. Oral Antifungals
  2. Laser Therapy
  3. Photodynamic Therapy
  4. Combination Therapy
5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025 - 2032
  1. Distal Subungual Onychomycosis
  2. White Superficial Onychomycosis
  3. Proximal Subungual Onychomycosis
  4. Candidal Onychomycosis
  5. Total Dystrophic Onychomycosis
6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025 - 2032
  1. Institutional Sales
    1. Hospitals
    2. Dermatology Clinics
  2. Retail Sales
    1. Retail Pharmacies
    2. Drug Stores
    3. Mail Order Pharmacies & Online Sales
7. Market Attractiveness Analysis
East Asia Dermatophytic Onychomycosis Therapeutics Market Outlook:
1. Key Highlights
2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2024
  1. By Country
  2. By Treatment Type
  3. By Indication
  4. By End User
3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025 - 2032
  1. China
  2. Japan
  3. South Korea
4. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2025 - 2032
  1. Drug-Based Treatment
    1. Topical Antifungals
    2. Oral Antifungals
  2. Laser Therapy
  3. Photodynamic Therapy
  4. Combination Therapy
5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025 - 2032
  1. Distal Subungual Onychomycosis
  2. White Superficial Onychomycosis
  3. Proximal Subungual Onychomycosis
  4. Candidal Onychomycosis
  5. Total Dystrophic Onychomycosis
6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025 - 2032
  1. Institutional Sales
    1. Hospitals
    2. Dermatology Clinics
  2. Retail Sales
    1. Retail Pharmacies
    2. Drug Stores
    3. Mail Order Pharmacies & Online Sales
7. Market Attractiveness Analysis
South Asia & Oceania Dermatophytic Onychomycosis Therapeutics Market Outlook:
1. Key Highlights
2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2024
  1. By Country
  2. By Treatment Type
  3. By Indication
  4. By End User
3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025 - 2032
  1. India
  2. Southeast Asia
  3. ANZ
  4. Rest of South Asia & Oceania
4. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2025 - 2032
  1. Drug-Based Treatment
    1. Topical Antifungals
    2. Oral Antifungals
  2. Laser Therapy
  3. Photodynamic Therapy
  4. Combination Therapy
5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025 - 2032
  1. Distal Subungual Onychomycosis
  2. White Superficial Onychomycosis
  3. Proximal Subungual Onychomycosis
  4. Candidal Onychomycosis
  5. Total Dystrophic Onychomycosis
6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025 - 2032
  1. Institutional Sales
    1. Hospitals
    2. Dermatology Clinics
  2. Retail Sales
    1. Retail Pharmacies
    2. Drug Stores
    3. Mail Order Pharmacies & Online Sales
7. Market Attractiveness Analysis
Latin America Dermatophytic Onychomycosis Therapeutics Market Outlook:
1. Key Highlights
2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2024
  1. By Country
  2. By Treatment Type
  3. By Indication
  4. By End User
3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025 - 2032
  1. Brazil
  2. Mexico
  3. Rest of Latin America
4. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2025 - 2032
  1. Drug-Based Treatment
    1. Topical Antifungals
    2. Oral Antifungals
  2. Laser Therapy
  3. Photodynamic Therapy
  4. Combination Therapy
5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025 - 2032
  1. Distal Subungual Onychomycosis
  2. White Superficial Onychomycosis
  3. Proximal Subungual Onychomycosis
  4. Candidal Onychomycosis
  5. Total Dystrophic Onychomycosis
6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025 - 2032
  1. Institutional Sales
    1. Hospitals
    2. Dermatology Clinics
  2. Retail Sales
    1. Retail Pharmacies
    2. Drug Stores
    3. Mail Order Pharmacies & Online Sales
7. Market Attractiveness Analysis
Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market Outlook:
1. Key Highlights
2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2024
  1. By Country
  2. By Treatment Type
  3. By Indication
  4. By End User
3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025 - 2032
  1. GCC Countries
  2. Egypt
  3. South Africa
  4. Northern Africa
  5. Rest of Middle East & Africa
4. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2025 - 2032
  1. Drug-Based Treatment
    1. Topical Antifungals
    2. Oral Antifungals
  2. Laser Therapy
  3. Photodynamic Therapy
  4. Combination Therapy
5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025 - 2032
  1. Distal Subungual Onychomycosis
  2. White Superficial Onychomycosis
  3. Proximal Subungual Onychomycosis
  4. Candidal Onychomycosis
  5. Total Dystrophic Onychomycosis
6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025 - 2032
  1. Institutional Sales
    1. Hospitals
    2. Dermatology Clinics
  2. Retail Sales
    1. Retail Pharmacies
    2. Drug Stores
    3. Mail Order Pharmacies & Online Sales
7. Market Attractiveness Analysis
Competition Landscape
1. Market Structure
  1. Competition Intensity Mapping By Market
  2. Competition Dashboard
2. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  1. Bausch Health
    1. Overview
    2. Segments and Treatment Types
    3. Key Financials
    4. Market Developments
    5. Market Strategy
  2. Galderma S.A.
  3. Novartis AG
  4. Pfizer, Inc.
  5. Moberg Pharma AB
  6. Bayer AG
  7. Dr. Reddy’s Laboratories Ltd.
  8. Cipla Ltd.
  9. Medimetriks Pharmaceuticals, Inc.
  10. Sanofi S.A.
  11. GlaxoSmithKline Plc.
  12. Teva Pharmaceutical industries Ltd.
  13. Cardinal Health Inc.
  14. Viatris Inc.
  15. Almirall, S.A
  16. Vanda Pharmaceuticals Inc.
  17. Others
Appendix
1. Research Methodology
2. Research Assumptions
3. Acronyms and Abbreviations

Global Market Attribute	Key Insights
Dermatophytic Onychomycosis Therapeutics Market Size (2025E)	US$ 7,074.7 Mn
Market Value Forecast (2032F)	US$ 10,602.8 Mn
Projected Growth (CAGR 2025 to 2032)	6.0%
Historical Market Growth (CAGR 2019 to 2024)	9.6%

Report Attribute	Details
Historical Data/Actuals	2019 - 2024
Forecast Period	2025 - 2032
Market Analysis Units	Value: US$ Mn
Geographical Coverage	North America Europe East Asia South Asia and Oceania Middle East and Africa Latin America
Segmental Coverage	Treatment Type Indication End-user Region
Competitive Analysis	Bausch Health Galderma S.A. Novartis AG Pfizer, Inc. Moberg Pharma AB Bayer AG Dr. Reddy’s Laboratories Ltd. Cipla Ltd. Medimetriks Pharmaceuticals, Inc. Sanofi S.A. GlaxoSmithKline Plc. Teva Pharmaceutical Industries Ltd. Cardinal Health Inc. Viatris Inc. Almirall, S.A Vanda Pharmaceuticals Inc. Others
Report Highlights	Market Forecast and Trends Competitive Intelligence & Share Analysis Growth Factors and Challenges Strategic Growth Initiatives Future Opportunities and Revenue Pockets
Customization and Pricing	Available upon request

Global Market Attribute	Key Insights
Dermatophytic Onychomycosis Therapeutics Market Size (2025E)	US$ 7,074.7 Mn
Market Value Forecast (2032F)	US$ 10,602.8 Mn
Projected Growth (CAGR 2025 to 2032)	6.0%
Historical Market Growth (CAGR 2019 to 2024)	9.6%

Report Attribute	Details
Historical Data/Actuals	2019 - 2024
Forecast Period	2025 - 2032
Market Analysis Units	Value: US$ Mn
Geographical Coverage	North America Europe East Asia South Asia and Oceania Middle East and Africa Latin America
Segmental Coverage	Treatment Type Indication End-user Region
Competitive Analysis	Bausch Health Galderma S.A. Novartis AG Pfizer, Inc. Moberg Pharma AB Bayer AG Dr. Reddy’s Laboratories Ltd. Cipla Ltd. Medimetriks Pharmaceuticals, Inc. Sanofi S.A. GlaxoSmithKline Plc. Teva Pharmaceutical Industries Ltd. Cardinal Health Inc. Viatris Inc. Almirall, S.A Vanda Pharmaceuticals Inc. Others
Report Highlights	Market Forecast and Trends Competitive Intelligence & Share Analysis Growth Factors and Challenges Strategic Growth Initiatives Future Opportunities and Revenue Pockets
Customization and Pricing	Available upon request

Dermatophytic Onychomycosis Therapeutics Market Size, Share, Trends, Growth, and Regional Forecasts 2025 - 2032

Dermatophytic Onychomycosis Therapeutics Market by Treatment Type (Drug-Based Treatment, Laser Therapy, Photodynamic Therapy, Combination Therapy), by Indication, by End-user, and Regional Analysis for 2025 - 2032